Intrinsically cell-penetrating multivalent and multitargeting ligands for myotonic dystrophy type 1

Ju Yeon Lee, Yugang Bai, Ullas V. Chembazhi, Shaohong Peng, Kevin Yum, Long M. Luu, Lauren D. Hagler, Julio F. Serrano, H. Y. Edwin Chan, Auinash Kalsotra, Steven C Zimmerman

Research output: Contribution to journalArticle

Abstract

Developing highly active, multivalent ligands as therapeutic agents is challenging because of delivery issues, limited cell permeability, and toxicity. Here, we report intrinsically cell-penetrating multivalent ligands that target the trinucleotide repeat DNA and RNA in myotonic dystrophy type 1 (DM1), interrupting the disease progression in two ways. The oligomeric ligands are designed based on the repetitive structure of the target with recognition moieties alternating with bisamidinium groove binders to provide an amphiphilic and polycationic structure, mimicking cell-penetrating peptides. Multiple biological studies suggested the success of our multivalency strategy. The designed oligomers maintained cell permeability and exhibited no apparent toxicity both in cells and in mice at working concentrations. Furthermore, the oligomers showed important activities in DM1 cells and in a DM1 liver mouse model, reducing or eliminating prominent DM1 features. Phenotypic recovery of the climbing defect in adult DM1 Drosophila was also observed. This design strategy should be applicable to other repeat expansion diseases and more generally to DNA/RNA-targeted therapeutics.

Original languageEnglish (US)
Pages (from-to)8709-8714
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume116
Issue number18
DOIs
StatePublished - Apr 30 2019

Fingerprint

Myotonic Dystrophy
Ligands
Permeability
Cell-Penetrating Peptides
RNA
Trinucleotide Repeats
DNA
Drosophila
Disease Progression
Liver
Therapeutics

Keywords

  • Cell-penetrating peptide mimic
  • DNA/RNA-targeting therapeutics
  • Multivalent ligand
  • Myotonic dystrophy type 1
  • Trinucleotide repeat expansion diseases

ASJC Scopus subject areas

  • General

Cite this

Intrinsically cell-penetrating multivalent and multitargeting ligands for myotonic dystrophy type 1. / Lee, Ju Yeon; Bai, Yugang; Chembazhi, Ullas V.; Peng, Shaohong; Yum, Kevin; Luu, Long M.; Hagler, Lauren D.; Serrano, Julio F.; Edwin Chan, H. Y.; Kalsotra, Auinash; Zimmerman, Steven C.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 116, No. 18, 30.04.2019, p. 8709-8714.

Research output: Contribution to journalArticle

Lee, Ju Yeon ; Bai, Yugang ; Chembazhi, Ullas V. ; Peng, Shaohong ; Yum, Kevin ; Luu, Long M. ; Hagler, Lauren D. ; Serrano, Julio F. ; Edwin Chan, H. Y. ; Kalsotra, Auinash ; Zimmerman, Steven C. / Intrinsically cell-penetrating multivalent and multitargeting ligands for myotonic dystrophy type 1. In: Proceedings of the National Academy of Sciences of the United States of America. 2019 ; Vol. 116, No. 18. pp. 8709-8714.
@article{d7d3d97d5e35483fa6ffe987b62f0619,
title = "Intrinsically cell-penetrating multivalent and multitargeting ligands for myotonic dystrophy type 1",
abstract = "Developing highly active, multivalent ligands as therapeutic agents is challenging because of delivery issues, limited cell permeability, and toxicity. Here, we report intrinsically cell-penetrating multivalent ligands that target the trinucleotide repeat DNA and RNA in myotonic dystrophy type 1 (DM1), interrupting the disease progression in two ways. The oligomeric ligands are designed based on the repetitive structure of the target with recognition moieties alternating with bisamidinium groove binders to provide an amphiphilic and polycationic structure, mimicking cell-penetrating peptides. Multiple biological studies suggested the success of our multivalency strategy. The designed oligomers maintained cell permeability and exhibited no apparent toxicity both in cells and in mice at working concentrations. Furthermore, the oligomers showed important activities in DM1 cells and in a DM1 liver mouse model, reducing or eliminating prominent DM1 features. Phenotypic recovery of the climbing defect in adult DM1 Drosophila was also observed. This design strategy should be applicable to other repeat expansion diseases and more generally to DNA/RNA-targeted therapeutics.",
keywords = "Cell-penetrating peptide mimic, DNA/RNA-targeting therapeutics, Multivalent ligand, Myotonic dystrophy type 1, Trinucleotide repeat expansion diseases",
author = "Lee, {Ju Yeon} and Yugang Bai and Chembazhi, {Ullas V.} and Shaohong Peng and Kevin Yum and Luu, {Long M.} and Hagler, {Lauren D.} and Serrano, {Julio F.} and {Edwin Chan}, {H. Y.} and Auinash Kalsotra and Zimmerman, {Steven C}",
year = "2019",
month = "4",
day = "30",
doi = "10.1073/pnas.1820827116",
language = "English (US)",
volume = "116",
pages = "8709--8714",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "18",

}

TY - JOUR

T1 - Intrinsically cell-penetrating multivalent and multitargeting ligands for myotonic dystrophy type 1

AU - Lee, Ju Yeon

AU - Bai, Yugang

AU - Chembazhi, Ullas V.

AU - Peng, Shaohong

AU - Yum, Kevin

AU - Luu, Long M.

AU - Hagler, Lauren D.

AU - Serrano, Julio F.

AU - Edwin Chan, H. Y.

AU - Kalsotra, Auinash

AU - Zimmerman, Steven C

PY - 2019/4/30

Y1 - 2019/4/30

N2 - Developing highly active, multivalent ligands as therapeutic agents is challenging because of delivery issues, limited cell permeability, and toxicity. Here, we report intrinsically cell-penetrating multivalent ligands that target the trinucleotide repeat DNA and RNA in myotonic dystrophy type 1 (DM1), interrupting the disease progression in two ways. The oligomeric ligands are designed based on the repetitive structure of the target with recognition moieties alternating with bisamidinium groove binders to provide an amphiphilic and polycationic structure, mimicking cell-penetrating peptides. Multiple biological studies suggested the success of our multivalency strategy. The designed oligomers maintained cell permeability and exhibited no apparent toxicity both in cells and in mice at working concentrations. Furthermore, the oligomers showed important activities in DM1 cells and in a DM1 liver mouse model, reducing or eliminating prominent DM1 features. Phenotypic recovery of the climbing defect in adult DM1 Drosophila was also observed. This design strategy should be applicable to other repeat expansion diseases and more generally to DNA/RNA-targeted therapeutics.

AB - Developing highly active, multivalent ligands as therapeutic agents is challenging because of delivery issues, limited cell permeability, and toxicity. Here, we report intrinsically cell-penetrating multivalent ligands that target the trinucleotide repeat DNA and RNA in myotonic dystrophy type 1 (DM1), interrupting the disease progression in two ways. The oligomeric ligands are designed based on the repetitive structure of the target with recognition moieties alternating with bisamidinium groove binders to provide an amphiphilic and polycationic structure, mimicking cell-penetrating peptides. Multiple biological studies suggested the success of our multivalency strategy. The designed oligomers maintained cell permeability and exhibited no apparent toxicity both in cells and in mice at working concentrations. Furthermore, the oligomers showed important activities in DM1 cells and in a DM1 liver mouse model, reducing or eliminating prominent DM1 features. Phenotypic recovery of the climbing defect in adult DM1 Drosophila was also observed. This design strategy should be applicable to other repeat expansion diseases and more generally to DNA/RNA-targeted therapeutics.

KW - Cell-penetrating peptide mimic

KW - DNA/RNA-targeting therapeutics

KW - Multivalent ligand

KW - Myotonic dystrophy type 1

KW - Trinucleotide repeat expansion diseases

UR - http://www.scopus.com/inward/record.url?scp=85065511299&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065511299&partnerID=8YFLogxK

U2 - 10.1073/pnas.1820827116

DO - 10.1073/pnas.1820827116

M3 - Article

VL - 116

SP - 8709

EP - 8714

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 18

ER -